Separate studies have demonstrated that increased plasma IL-17 levels correlate with poor prognosis in AML [77,78], although the direct relationship between bona fide ILC3 and IL-17 in the setting of de novo AML is currently not known. Here, IL17A is linked to acute myeloid leukemia.